Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GSR | P00390 | 1/20 | 0.53 |
| ▸ | OTC | P00480 | 1/20 | 0.44 |
| ▸ | GNAI3 | P08754 | 1/20 | 0.43 |
| ▸ | GNAO1 | P09471 | 1/20 | 0.43 |
| ▸ | GNAI1 | P63096 | 1/20 | 0.43 |
| ▸ | ACHE | P22303 | 7/20 | 0.42 |
| ▸ | DDAH1 | O94760 | 1/20 | 0.42 |
| ▸ | DPP8 | Q6V1X1 | 1/20 | 0.42 |
| ▸ | DPP7 | Q9UHL4 | 1/20 | 0.42 |
| ▸ | ARG2 | P78540 | 4/20 | 0.41 |
| ▸ | ARG1 | P05089 | 3/20 | 0.41 |
| ▸ | ANPEP | P15144 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24945952 | 1.00 | GSR (0.53) | GSROTCGNAI3GNAO1GNAI1 | |
| SCHEMBL18924694 | 1.00 | GSR (0.53) | GSROTCGNAI3GNAO1GNAI1 | |
| SCHEMBL20192790 | 0.95 | GSR (0.50) | GSROTCACHEDDAH1ARG2 | |
| SCHEMBL20192789 | 0.92 | GSR (0.56) | GSROTCGNAI3GNAO1GNAI1 | |
| SCHEMBL19246101 | 0.89 | GSR (0.56) | GSROTCGNAI3GNAO1GNAI1 | |
| SCHEMBL18924756 | 0.88 | GSR (0.53) | GSROTCACHEDDAH1ARG2 | |
| SCHEMBL19966765 | 0.87 | GSR (0.52) | GSROTCGNAI3GNAO1GNAI1 | |
| SCHEMBL23608137 | 0.86 | ACHE (0.53) | GNAI3GNAO1GNAI1ACHEDPP7 | |
| SCHEMBL23385458 | 0.86 | ACHE (0.53) | GNAI3GNAO1GNAI1ACHEDPP7 | |
| SCHEMBL23607693 | 0.86 | ACHE (0.53) | GNAI3GNAO1GNAI1ACHEDPP7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2024040453-A1 | MUTATED INFLUENZA VIRUS, PHARMACEUTICAL COMPOSITION, AND USE | 北京大学宁波海洋药物研究院 | 2024-02-29 | — | — | WO | disclosed |
| US-20230183298-A1 | CARRIER PROTEIN SUBJECTED TO SITE-DIRECTED MUTATION AND USE THEREOF IN PREPARATION OF VACCINE | CANSINO BIOLOGICS INC. (CN) | 2023-06-15 | — | — | US | disclosed |
| WO-2021133839-A1 | METHODS OF PREPARING N6-((2-AZIDOETHOXY)CARBONYL)LYSINE | Synthorx, Inc. (US) | 2021-07-01 | — | — | WO | disclosed |
| US-20200268870-A1 | MUTANT VIRUS, PREPARATION METHOD THEREFOR AND APPLICATION THEREOF | PEKING UNIVERSITY (CN) | 2020-08-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200268870-A1 | MUTANT VIRUS, PREPARATION METHOD THEREFOR AND APPLICATION THEREOF | UPF1, CPSF7, CPSF1 | GSR 2114/4885OTC 1459/4885GNAI3 1038/4885 |
| US-20230183298-A1 | CARRIER PROTEIN SUBJECTED TO SITE-DIRECTED MUTATION AND USE THEREOF IN PREPARATION OF VACCINE | PCTP, PLTP, ASGR1 | GSR 829/4885OTC 1286/4885GNAI3 1671/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.